Innovative alternatives for metastatic CRPC after enzalutamide

Medina, Camilo; Ritter, César Diaz

doi:10.1016/s1470-2045(22)00751-3

Cited by 1 publication

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The primary treatments for early-stage PCa currently include surgery and androgen deprivation therapy (ADT) [ 7 ]. However, a significant number of patients with PCa inevitably progress to castration-resistant PCa (CRPC), which is associated with poor prognosis [ 8 , 9 ]. Therefore, understanding the pathogenesis of PCa and identifying new therapeutic targets are critically important.…”

Section: Introductionmentioning

confidence: 99%

Cell division cycle 42 effector protein 4 inhibits prostate cancer progression by suppressing ERK signaling pathway

Zhang,

Yu,

Gao

et al. 2023

Biomol Biomed

View full text Add to dashboard Cite

Prostate cancer (PCa) is the most common malignancy among men worldwide. The cell division cycle 42 effector protein 4 (CDC42EP4) functions downstream of CDC42, yet its role and molecular mechanisms in PCa remain unexplored. This study aimed to elucidate the role of CDC42EP4 in the progression of PCa and its underlying mechanisms. Bioinformatical analysis indicated that CDC42EP4 expression was significantly lower in PCa tissue compared to normal prostate tissue. Cellular phenotyping analysis suggested that CDC42EP4 markedly inhibited the proliferation, migration, and invasion of PCa cells. Xenograft tumor assays further demonstrated that CDC42EP4 suppressed the growth of PCa cells in vivo. Mechanistically, the study established that CDC42EP4 inhibited the ERK pathway in PCa cells. Additionally, the ERK pathway inhibitor PD0325901 was employed, revealing that PD0325901 significantly nullified the effects of CDC42EP4 on PCa cell proliferation, migration, and invasion. Collectively, our findings demonstrate that CDC42EP4 acts as a critical tumor suppressor gene, inhibiting PCa cell proliferation, migration, and invasion through the ERK pathway, thereby presenting potential targets for PCa therapy.

show abstract

Section: Introductionmentioning

confidence: 99%